Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Abvc Biopharma Q3 2026 Results: Turns Profitable, Net Income $1.15M

ABVC BioPharma reported accrued research and development expenses of $1,741,083 as of September 30, 2026, primarily for manufacturing and process development. The company noted potential increases in future accruals due to the planned resumption of ophthalmology and CNS clinical trials.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-1.4-2.1
Net income1.1-2.0
EPS (diluted, $ a share)$0.04$-0.09

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ABVC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Abvc Biopharma, Inc.: key numbers

Share price
$0.9400Close, Nov 16
Market cap
$25.4M
Shares outstanding
26.98MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Abvc Biopharma, Inc.

All →
9:52 AM ET 8-K
Loan & Debt

Abvc Biopharma $4.11M Debt Financing with WallachBeth Capital, LLC

ABVC BioPharma entered into a securities purchase agreement for the sale of original issue discount senior convertible promissory notes in an aggregate principal amount of $4,106,060. The notes carry a 17.5% original issue discount, generating gross proceeds of $3.39 million, and mature on June 30, 2027. Proceeds will be used for working capital and to fund a $625,000 settlement payment to Lind Global Fund II LP.

Value
$4.11M
Counterparty
WallachBeth Capital, LLC
Term
through June 30, 2027

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.